The board of directors of AcuCort AB (“the Company” or “AcuCort”) has prepared an EU growth prospectus (“the Prospectus”) in connection with the issuance of units with preferential rights for AcuCort’s shareholders (“the Preferential Rights Issue”) decided by the board on August 31, 2023, and approved by the extraordinary general meeting on October 2, 2023.
Summary of the Preferential Rights Issue
Shareholders in AcuCort received one (1) unit right per share held on the record date of October 10, 2023. Five (5) unit rights entitle the holder to subscribe for one (1) unit. One (1) unit consists of twelve (12) shares and eight (8) free-of-charge warrants. The subscription price per unit is SEK 4.80, equivalent to SEK 0.40 per share. Trading of unit rights takes place from October 12, 2023, to October 23, 2023. The subscription period runs from October 12, 2023, to October 26, 2023. One (1) warrant entitles the holder to subscribe for one (1) share during the period from March 6, 2024, to March 20, 2024. The subscription price is SEK 0.40 per share. The Preferential Rights Issue is secured to approximately 70 percent through subscription and guarantee commitments. Upon full subscription in the Preferential Rights Issue, the Company will receive approximately SEK 30 million before issuance costs. Upon full exercise of the warrants, the Company may receive an additional up to SEK 20 million before issuance costs. For more information on the Preferential Rights Issue, please refer to the Prospectus.